Aktis Oncology (NASDAQ:AKTS) Major Shareholder Vida Ventures Ii, Llc Acquires 835,000 Shares

Aktis Oncology (NASDAQ:AKTS) major shareholder Vida Ventures Ii, Llc bought 835,000 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were bought at an average price of $18.00 per share, for a total transaction of $15,030,000.00. Following the acquisition, the insider directly owned 5,671,825 shares of the company’s stock, valued at $102,092,850. This represents a 17.26% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Aktis Oncology Stock Down 2.9%

Shares of NASDAQ:AKTS traded down $0.65 during trading on Monday, hitting $21.75. 829,486 shares of the company were exchanged, compared to its average volume of 39,873,640. Aktis Oncology has a fifty-two week low of $19.33 and a fifty-two week high of $29.16. The stock has a market cap of $3.36 billion, a price-to-earnings ratio of -58.78 and a beta of 1.91. The company has a current ratio of 0.32, a quick ratio of 0.28 and a debt-to-equity ratio of 1.00. The firm has a fifty day moving average price of $0.07 and a two-hundred day moving average price of $0.09.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.